Arizona State Retirement System Acquires 1,628 Shares of Catalent, Inc. (NYSE:CTLT)

Posted by on May 10th, 2023

Arizona State Retirement System increased its position in shares of Catalent, Inc. (NYSE:CTLT – Get Rating) by 3.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 48,374 shares of the company’s stock after buying an additional 1,628 shares during the period. Arizona State Retirement System’s holdings in Catalent were worth $2,177,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Texas Permanent School Fund grew its holdings in shares of Catalent by 0.8% during the fourth quarter. Texas Permanent School Fund now owns 25,569 shares of the company’s stock valued at $1,151,000 after buying an additional 212 shares during the last quarter. Toronto Dominion Bank grew its stake in Catalent by 23.8% in the 4th quarter. Toronto Dominion Bank now owns 92,083 shares of the company’s stock worth $4,142,000 after buying an additional 17,717 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in Catalent by 5.2% in the 4th quarter. Commonwealth Equity Services LLC now owns 6,724 shares of the company’s stock worth $302,000 after buying an additional 335 shares in the last quarter. Metis Global Partners LLC boosted its stake in shares of Catalent by 36.5% in the 4th quarter. Metis Global Partners LLC now owns 4,902 shares of the company’s stock valued at $221,000 after purchasing an additional 1,311 shares in the last quarter. Finally, Veritas Asset Management LLP grew its holdings in Catalent by 60.5% in the 4th quarter. Veritas Asset Management LLP now owns 11,169,815 shares of the company’s stock worth $502,753,000 after acquiring an additional 4,212,040 shares during the last quarter. 99.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Mario Gargiulo sold 678 shares of the business’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $49.86, for a total transaction of $33,805.08. Following the completion of the sale, the senior vice president now owns 5,676 shares in the company, valued at $283,005.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, SVP Mario Gargiulo sold 678 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $49.86, for a total transaction of $33,805.08. Following the completion of the sale, the senior vice president now owns 5,676 shares in the company, valued at $283,005.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Manja Boerman sold 1,446 shares of the company’s stock in a transaction on Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $72,097.56. Following the transaction, the insider now directly owns 14,414 shares in the company, valued at approximately $718,682.04. The disclosure for this sale can be found here. 0.58% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Royal Bank of Canada dropped their target price on shares of Catalent from $58.00 to $41.00 in a research report on Monday. Bank of America lowered shares of Catalent from a “neutral” rating to an “underperform” rating and set a $28.00 price target for the company. in a research note on Monday. Deutsche Bank Aktiengesellschaft cut their target price on shares of Catalent from $72.00 to $55.00 in a research report on Tuesday. Barclays lowered their price target on shares of Catalent from $70.00 to $40.00 in a report on Monday, April 17th. Finally, William Blair downgraded shares of Catalent from an “outperform” rating to a “market perform” rating in a report on Friday, April 14th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $77.40.

Catalent Stock Down 1.2 %

Shares of NYSE:CTLT opened at $35.04 on Wednesday. The business has a 50-day moving average price of $58.96 and a 200 day moving average price of $54.76. The company has a current ratio of 1.91, a quick ratio of 1.38 and a debt-to-equity ratio of 0.86. The company has a market capitalization of $6.31 billion, a price-to-earnings ratio of 15.50, a PEG ratio of 2.38 and a beta of 1.17. Catalent, Inc. has a 12-month low of $33.05 and a 12-month high of $115.33.

Catalent (NYSE:CTLT – Get Rating) last released its earnings results on Tuesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.64 by ($0.02). Catalent had a net margin of 8.62% and a return on equity of 11.40%. The firm had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.12 billion. Sell-side analysts expect that Catalent, Inc. will post 2.6 EPS for the current year.

Catalent Profile

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Further Reading

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.